aTYR PHARMA (ATYR) Cash from Investing Activities (2014 - 2026)

aTYR PHARMA (ATYR) has 13 years of Cash from Investing Activities data on file, last reported at $11.5 million in Q1 2026.

• Quarterly Cash from Investing Activities rose 360.05% year-over-year to $11.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.9 million (down 23.35% YoY) and the FY2025 annual result came in at -$5.1 million, down 129.32% from the prior year.
• Cash from Investing Activities declined to $11.5 million in Q1 2026, from $16.4 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $20.6 million in Q3 2022 to a low of -$38.2 million in Q1 2023.
• A 5-year average of $3.0 million and a median of $4.4 million in 2023 frame the typical range for Cash from Investing Activities.
• The widest YoY moves for Cash from Investing Activities: up 791.35% in 2023, down 360.99% in 2023.
• Tracing ATYR's Cash from Investing Activities over 5 years: stood at $2.0 million in 2022, then soared by 791.35% to $17.8 million in 2023, then plunged by 134.15% to -$6.1 million in 2024, then soared by 370.22% to $16.4 million in 2025, then sank by 30.1% to $11.5 million in 2026.
• The last three Cash from Investing Activities figures came in at $11.5 million (Q1 2026), $16.4 million (Q4 2025), and -$20.4 million (Q3 2025), per Business Quant data.